Contrasting Sensus Healthcare (NASDAQ:SRTS) and Venus Concept (NASDAQ:VERO)

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) and Venus Concept (NASDAQ:VERO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Earnings and Valuation

This table compares Sensus Healthcare and Venus Concept”s revenue, earnings per share and valuation.

Sensus Healthcare has higher earnings, but lower revenue than Venus Concept. Sensus Healthcare is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Sensus Healthcare has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Venus Concept has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Sensus Healthcare and Venus Concept, as reported by MarketBeat.

Sensus Healthcare presently has a consensus price target of $8.00, suggesting a potential upside of 111.36%. Given Sensus Healthcare’s stronger consensus rating and higher probable upside, equities analysts plainly believe Sensus Healthcare is more favorable than Venus Concept.

Institutional & Insider Ownership

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 8.9% of Sensus Healthcare shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Sensus Healthcare and Venus Concept’s net margins, return on equity and return on assets.

Summary

Sensus Healthcare beats Venus Concept on 10 of the 14 factors compared between the two stocks.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

About Venus Concept

(Get Free Report)

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.